1. Why Biocompatibility Testing Matters More Than Ever

Biocompatibility testing ensures that a medical device is:

• Non-toxic
• Non-irritant
• Non-sensitizing
• Compatible with blood, tissues and organs
• Safe for long-term use

Under the revised ISO 10993-1:2025, regulators expect deeper justification, clearer scientific reasoning and full traceability of risks. This means manufacturers must not only perform tests, but also explain why certain tests were selected or skipped.

Many devices fail approvals today because:

• Risk assessments are incomplete
• Biological endpoints are not justified
• Studies are not aligned with device material
• Documentation does not meet new global expectations

This makes choosing the right testing partner more important than ever.

2. Key Changes in ISO 10993-1:2025: What Manufacturers Must Know

The updated standard introduces several important changes:

➥ Stronger Risk-Based Evaluation

The new version requires a structured biological risk assessment before any tests begin. Manufacturers must justify:

• Potential hazards
• Patient contact duration
• Material composition
• Toxicity risks
• Need for additional tests

➥ Detailed Material Characterization

This includes chemical, physical and biological characterization. Regulators now demand evidence that manufacturers understand the materials used in their device.

➥ Greater Focus on Chemical Risks

If a device contains materials that may release chemicals, a deeper toxicological evaluation is required.

➥ Integrated Risk Documentation

Risk assessment must be connected to:

• E&L studies
• Toxicological profiles
• Material analysis
• Clinical evidence

This integrated approach improves patient safety and prevents approval delays.

3. What Accuprec Offers Under ISO 10993-1:2025

Accuprec provides complete biocompatibility testing services as per the revised guidelines.

A. In-Vitro Testing

These lab-based tests provide early-stage biological safety evaluation:

• Cytotoxicity
• Genotoxicity
• Hemolysis
• Various cell-culture tests

In-vitro testing is often the first step before moving to animal studies.

B. In-Vivo Testing

These tests help evaluate the safety of the device inside a living system:

• Irritation
• Sensitization
• Implantation studies
• Systemic toxicity
• Sub-chronic toxicity
• Chronic toxicity
• Carcinogenicity (if required)

Accuprec performs these studies following Good Laboratory Practices (GLP).

C. Hemocompatibility Studies

Required for blood-contacting devices:

• Coagulation
• Platelet activation
• Complement activation
• Hemolysis

D. Biological Evaluation Plan (BEP)

As per ISO 10993-1:2025, Accuprec prepares a complete biological evaluation plan that includes:

• Risk identification
• Biological endpoint mapping
• Material characterization
• Test justification
• Biological safety strategy

E. Biological Evaluation Report (BER)

After testing, Accuprec prepares a detailed BER that includes:

• Test data
• Risk assessment
• Chemical / toxicological evaluation
• Clinical justification
• Overall biological safety conclusion

A strong BER reduces chances of rejection by EU MDR and USFDA.

4. Why Medical Device Companies Choose Accuprec

• ➥ Expertise Under ISO 10993-1:2025 — Accuprec’s team includes toxicologists, biologists and regulatory experts who deeply understand the revised standard.
• ➥ All Tests Under One Roof — Manufacturers don’t have to depend on multiple labs. Accuprec provides complete biocompatibility testing including in-vitro, in-vivo, hemocompatibility and toxicological assessments.
• ➥ 250+ Technical Experts — Our team ensures that every study is scientifically strong and compliant with international expectations.
• ➥ Global Accreditations — Accuprec provides reports accepted by EU MDR, USFDA, WHO and CDSCO.
• ➥ Reduced Regulatory Risk — With risk-based planning and documentation, manufacturers avoid re-testing, delays, submission rejections and compliance gaps.
• ➥ Accurate, Precise and Timely Reports — Quick turnaround helps companies launch products faster.

5. Common Challenges in Biocompatibility — and How Accuprec Solves Them

• ❌ Challenge 1: Incomplete Risk Assessment — Accuprec creates detailed risk-based biological evaluation plans aligned with ISO 10993-1:2025.
• ❌ Challenge 2: Weak Test Justification — We scientifically justify every endpoint to avoid MDR or USFDA rejections.
• ❌ Challenge 3: Chemical Safety Concerns — Through E&L and toxicological support, Accuprec provides evidence to support chemical safety.
• ❌ Challenge 4: Improper Material Characterization — Accuprec performs deep material analysis to build a strong foundation for safety evaluation.
• ❌ Challenge 5: Poor Documentation — Accuprec prepares regulator-ready BERs that align with EU MDR expectations.

Conclusion

Biocompatibility testing is one of the most important steps in medical device approval. With ISO 10993-1:2025, regulators expect stronger risk-based evaluation and scientific justification. Accuprec is fully equipped to help manufacturers meet these expectations through comprehensive biocompatibility testing, expert risk assessment and globally acceptable documentation.

Accuprec ensures your device is safe, compliant and ready for international markets.